Catalent delays quarterly filing with SEC on $700 mln impairment charge

Catalent (CTLT.N) will delay its quarterly filing with the U.S. securities regulator due to a goodwill impairment charge of about $700 million related to acquisitions in the company's consumer health and biomodalities unit, the company said late Monday.